COMMUNIQUÉS West-GlobeNewswire

Inventiva to Present at 2026 Jefferies Global Healthcare Conference
21/05/2026
Daix (France), New York (United States), May 21, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies [...]
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
21/05/2026
– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant – – Data underscoring unique aspects of [...]
ODDIFACT Receives European Commission Orphan Drug Designation for Infliximab in Kawasaki Disease
21/05/2026
European designation follows U.S. FDA Orphan Drug Designation previously granted for the same indication Landmark KIDCARE trial demonstrated superiority of infliximab over standard retreatment in resistant Kawasaki [...]
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
21/05/2026
In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of high-grade adverse events Activity of the combined regimen across all dose [...]
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
21/05/2026
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical [...]
Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21/05/2026
SAN JOSE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first of-its-kind technology to improve clinical outcomes in dialysis with less cost and [...]
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
21/05/2026
Cash Runway Extended to Finance the Parkinson’s Program; Debt Paydown Improves Shareholder Equity Position Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the " [...]
Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026
21/05/2026
Not intended for US and UK media New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS ® (zongertinib tablets) as an initial treatment option in HER2 ( ERBB2 )-mutant [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
21/05/2026
CONSHOHOCKEN, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis [...]
Lunavelle Sleep Patches Claims Evaluated: Most Effective Melatonin-Free Patches for Deeper Rest with Time-Tested Ingredients Proven To Work
21/05/2026
Lunavelle Sleep Patches Research, Ingredients, Side Effects, and Refund Policy Explained: Magnesium Glycinate, L-Theanine, GABA, and Valerian Root Formula San Francisco, CA, May 21, 2026 (GLOBE NEWSWIRE) -- These [...]
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
21/05/2026
Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Combined results evaluating AKY-2519 across several B7-H3 expressing tumor types, including metastatic [...]
Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
21/05/2026
REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
21/05/2026
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage therapeutics company focused on developing transformative therapies targeting functional cures for immunological disorders, [...]
Seven Arrows Recovery Expands Public Education Efforts Around Forward Facing, Nervous System Centered Addiction Treatment
21/05/2026
The Arizona residential treatment center introduces broader awareness of its trauma informed and salutogenic recovery model through Forward Facing Accelerated Recovery™ Elfrida, ARIZONA, May 21, 2026 (GLOBE NEWSWIRE [...]
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
21/05/2026
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody [...]
IQity and Sightpath Medical Partner to Deliver Advanced Ophthalmic Technology to Surgeons Nationwide
21/05/2026
RENO, Nev., May 21, 2026 (GLOBE NEWSWIRE) -- IQity, the developer of a revolutionary integrated diagnostic and surgical platform for modern ophthalmology, today announced a strategic partnership with Sightpath Medical, [...]
BulkGLP Announces Dual-Tier Quality Verification Protocol for Global Supply of Analytical Reference Materials
21/05/2026
Exclusive manufacturing partnership integrates point-of-origin batch testing in Malaysia with strict domestic HPLC and LC-MS verification to ensure uncompromising purity for laboratory reagents. BulkGLP Logo DALLAS, May [...]
GENFIT : Information financière du premier trimestre 2026 et point sur les activités de la Société
21/05/2026
Trésorerie et équivalents de trésorerie s’élevant à 136,1 millions d’euros au 31 mars 2026 Chiffre d’affaires de 9,6 millions d’euros pour les trois premiers mois de 2026, provenant des redevances issues des ventes d’ [...]
NANOBIOTIX annonce les modalites definitives de son offre globale sursouscrite a hauteur de 85 millions d’euros
21/05/2026
PARIS et CAMBRIDGE, Mass., 21 mai 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – « Nanobiotix » ou la « Société »), une société de biotechnologie au stade clinique et en phase avancée qui développe [...]

Pages